Profile data is unavailable for this security.
About the company
Liaoning Chengda Biotechnology Co Ltd is a China-based company mainly engaged in the research, production, and sales of human vaccines. The Company's main products include rabies vaccine for human use, freeze-dried rabies vaccine for human use, inactivated Japanese encephalitis vaccine for human use and freeze-dried encephalitis inactivated vaccine. The Company's products include two brands: Chengda Suda and Chengda Libao.
- Revenue in CNY (TTM)1.72bn
- Net income in CNY332.10m
- Incorporated2002
- Employees1.73k
- LocationLiaoning Chengda Biotechnology Co LtdNo. 1Xinfang Street, Hunnan New DistrictSHENYANG 110179ChinaCHN
- Phone+86 2 483782632
- Fax+86 2 423789772
- Websitehttp://www.cdbio.cn
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mayinglong Pharmaceutical Group Co Ltd | 3.48bn | 482.37m | 10.99bn | 2.88k | 22.79 | 2.75 | -- | 3.16 | 1.12 | 1.12 | 8.08 | 9.28 | 0.6872 | 6.42 | 8.53 | 1,208,299.00 | 9.74 | 10.82 | 11.64 | 13.47 | 44.84 | 41.18 | 14.17 | 14.08 | 4.40 | -- | 0.0936 | 33.04 | -11.20 | 7.38 | -7.46 | 20.26 | 58.33 | 21.67 |
| Changchun BCHT Biotechnology Co | 1.61bn | 414.29m | 11.07bn | 1.24k | 26.74 | 2.64 | -- | 6.89 | 1.00 | 1.00 | 3.88 | 10.15 | 0.3181 | 1.00 | 1.06 | 1,295,333.00 | 8.20 | 9.95 | 10.23 | 12.81 | 87.55 | 86.63 | 25.77 | 24.03 | 1.85 | -- | 0.0147 | 10.55 | 70.30 | 12.36 | 175.98 | 31.37 | 21.04 | -- |
| Heilongjiang ZBD Pharmaceutical Co Ltd | 2.58bn | 114.60m | 11.23bn | 2.55k | 99.86 | 1.45 | -- | 4.35 | 0.1194 | 0.1194 | 2.74 | 8.24 | 0.2118 | 1.48 | 0.7645 | 1,014,704.00 | 0.8822 | 3.48 | 1.17 | 4.78 | 34.52 | 38.93 | 4.17 | 10.08 | 2.23 | -- | 0.2888 | 27.18 | -25.50 | 2.45 | 155.00 | 0.4417 | -25.68 | 4.05 |
| Cansino Biologics Inc | 748.53m | -720.11m | 11.30bn | 1.49k | -- | 3.28 | -- | 15.10 | -2.92 | -2.92 | 3.03 | 20.46 | 0.0851 | 0.6341 | 1.12 | 501,023.80 | -8.41 | -4.27 | -11.09 | -5.59 | 67.71 | 41.73 | -98.82 | -27.60 | 2.27 | -8.75 | 0.2934 | -- | -65.49 | 163.48 | -63.04 | -- | 30.60 | -- |
| KPC Pharmaceuticals Inc | 7.55bn | 446.07m | 11.42bn | 5.05k | 25.46 | 2.06 | -- | 1.51 | 0.5924 | 0.5924 | 10.03 | 7.31 | 0.7819 | 2.75 | 2.56 | 1,494,697.00 | 4.64 | 5.42 | 7.75 | 9.13 | 40.84 | 43.68 | 5.94 | 5.70 | 1.51 | -- | 0.172 | 35.75 | -6.99 | 1.64 | 16.05 | 5.79 | -21.33 | 14.87 |
| Liaoning Chengda Biotechnology Co Ltd | 1.72bn | 332.10m | 11.54bn | 1.73k | 34.50 | 1.21 | -- | 6.72 | 0.8032 | 0.8032 | 4.16 | 22.93 | 0.1702 | 0.763 | 1.43 | 991,973.80 | 3.29 | 10.63 | 3.41 | 11.01 | 80.53 | 85.74 | 19.33 | 39.56 | 17.44 | -- | 0.0018 | 31.53 | -3.58 | 4.71 | -34.75 | -5.56 | 39.78 | -- |
| Jiangsu Sinopep Allsin Bphrmctcl Co Ltd | 1.58bn | 421.47m | 12.04bn | 1.55k | 29.07 | 4.60 | -- | 7.64 | 1.88 | 1.88 | 7.14 | 11.91 | 0.4286 | 1.19 | 3.67 | 1,020,281.00 | 11.58 | 5.86 | 16.99 | 7.59 | 67.12 | 55.41 | 27.01 | 17.20 | 0.912 | 24.02 | 0.3477 | 27.59 | 58.69 | 32.24 | 26.20 | 29.99 | 27.32 | -- |
| Guobang Pharma Ltd | 5.71bn | 702.28m | 12.13bn | 4.23k | 17.22 | 1.55 | -- | 2.12 | 1.26 | 1.26 | 10.26 | 14.03 | 0.5599 | 3.29 | 7.84 | 1,350,536.00 | 6.87 | 10.36 | 8.88 | 14.24 | 23.87 | 27.49 | 12.27 | 15.01 | 1.70 | -- | 0.1992 | 18.24 | -6.49 | 10.28 | -33.49 | 23.77 | 35.60 | -- |
Data as of Sep 13 2024. Currency figures normalised to Liaoning Chengda Biotechnology Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
6.30%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| GF Securities Asset Management (Guangdong) Co., Ltd.as of 11 Mar 2024 | 2.75m | 1.54% |
| Bosera Asset Management Co., Ltd.as of 30 Jun 2024 | 1.91m | 1.07% |
| Penghua Fund Management Co., Ltd.as of 30 Jun 2024 | 1.75m | 0.98% |
| The Vanguard Group, Inc.as of 06 Nov 2024 | 1.01m | 0.57% |
| China Southern Asset Management Co., Ltd.as of 30 Jun 2024 | 970.49k | 0.54% |
| Yinhua Fund Management Co., Ltd.as of 30 Jun 2024 | 665.57k | 0.37% |
| China Universal Asset Management Co., Ltd.as of 30 Jun 2024 | 636.12k | 0.36% |
| Guotai Asset Management Co., Ltd.as of 30 Jun 2024 | 566.38k | 0.32% |
| China Asset Management Co., Ltd.as of 30 Jun 2024 | 559.89k | 0.31% |
| GF Fund Management Co., Ltd.as of 30 Jun 2024 | 447.81k | 0.25% |
More ▼
Data from 30 Jun 2024 - 11 Nov 2024Source: FactSet Research Systems Inc.
